Cargando…

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Detalles Bibliográficos
Autores principales:	Borchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash, Timmerman, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621474/ http://dx.doi.org/10.1097/01.HS9.0000890812.66186.e8

Ejemplares similares

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
por: Gregory, G., et al.
Publicado: (2022)

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Johnson, Nathalie, et al.
Publicado: (2023)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
por: Timmerman, John, et al.
Publicado: (2023)

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
por: Herrera, A. F., et al.
Publicado: (2022)

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
por: Garralda, E., et al.
Publicado: (2022)

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Armand, Philippe, et al.
Publicado: (2023)

ODP061 When cortisol and catecholamines combine in a severe endocrine condition
por: Webster, John, et al.
Publicado: (2022)

T cell activation and anti-tumor efficacy of anti-LAG-3 antibodies is independent of LAG-3 – MHCII blocking capacity
por: Cemerski, Saso, et al.
Publicado: (2015)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
por: Tobin, Joshua W. D., et al.
Publicado: (2021)

Dimension milestone - Release 0.6.1 of dimensions
por: Hoffmann, H, et al.
Publicado: (1996)

Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study
por: Esser, Peter, et al.
Publicado: (2023)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
por: Van Cutsem, Eric, et al.
Publicado: (2021)

Bacillus sp. BS061 Suppresses Powdery Mildew and Gray Mold
por: Kim, Young-Sook, et al.
Publicado: (2013)

SAT-061 Severe Hypocalcemia in an Infant with Abnormal Microarray and Dysmorphic Features
por: Jo, Inha, et al.
Publicado: (2020)

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
por: Huuhtanen, Jani, et al.
Publicado: (2023)

Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia
por: Luyt, Charles-Edouard, et al.
Publicado: (2009)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

CLL and COVID-19: light at the end of the tunnel?
por: Scarfò, Lydia, et al.
Publicado: (2022)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

P061. Clinical characteristics of elderly with headache in an outpatient geriatric setting in Italy
por: Soldato, Manuel, et al.
Publicado: (2015)

AB061. Trickier and tips for surgical treatment of complex male urethral fistula
por: Wang, Kunjie, et al.
Publicado: (2015)

O061. Frontal thermography in healthy individuals and headache patients: reliability of the method
por: Voiticovschi-Iosob, Cristina, et al.
Publicado: (2015)

P061 The effect of anxiety on symptom burden in patients with obstructive sleep apnoea
por: Kelley, L, et al.
Publicado: (2021)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

SAT-061 Determinants of Cosyntropin Effect on Adrenal Vein Sampling Lateralization in Primary Aldosteronism
por: Wannachalee, Taweesak, et al.
Publicado: (2019)

Maize Ethylene Response Factor ZmERF061 Is Required for Resistance to Exserohilum turcicum
por: Zang, Zhenyuan, et al.
Publicado: (2021)

LBODP061 A Pilot Trial Of Continuous Glucose Monitoring Technology In The Perioperative Period
por: Price, Catherine E, et al.
Publicado: (2022)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

Rituximab-Related Pulmonary Toxicity
por: Herishanu, Yair, et al.
Publicado: (2010)

The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge
por: Bronstein, Yotam, et al.
Publicado: (2022)

Adaptive Lag Smoother for State Estimation
por: Poddar, Shashi, et al.
Publicado: (2022)

SAT061 Deficiency Of ENaC Excites Pancreatic β Cells To Promote Insulin Secretion
por: Que, Yanting, et al.
Publicado: (2023)

Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
por: Lauder, Sarah N., et al.
Publicado: (2021)

Therapeutic Effects of Novel Sphingosine-1-Phosphate Receptor Agonist W-061 in Murine DSS Colitis
por: Sanada, Yasuaki, et al.
Publicado: (2011)

AB061. Clinical analysis of small cell carcinoma of the bladder: 9 cases report and literature review
por: Chen, Zhi, et al.
Publicado: (2016)

Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061)
por: Chen, Iris, et al.
Publicado: (2016)

AB061. Can diffusion-weighted magnetic resonance imaging be efficient in the differential diagnosis of uronephrosis and pyonephrosis?
por: Gao, Xiaofeng, et al.
Publicado: (2018)

SUN-061 E-Cigarettes Alter Lipid Homeostasis and Cause Hepatic Steatosis in Diet-Induced Obesity
por: Hasan, Kamrul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_etdl36fr2mj05ibuvigs61hds9